BioSpace News Archive

Cold Genesys, Inc. today announced that it has entered into a clinical collaboration with Merck (known as MSD outside the United States and Canada) to evaluate the combination of Cold Genesys’ lead oncolytic immunotherapy candidate CG0070 with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), in a Phase 2 clinical study.

Distribution to Commence Today at 5:00pm ET

Liht Cannabis Corp. is a respondent in proceedings brought by the British Columbia Securities Commission as disclosed in a BCSC news release dated November 26, 2018.

Cost-benefit analysis by the University of Houston College of Pharmacy highlights clinical and economic benefits of novel device

Continuing to expand access to cancer care globally, Varian (NYSE: VAR) announced it was selected by Medical Specialist Holdings (MSH) to equip seven of its centers in South Africa with Varian linear accelerators and Eclipse™ treatment planning system.

Clinical Practice Guidelines Recognize Breast Cancer Index Clinical Utility Spans the Treatment Continuum for Patients with Early-Stage Estrogen Receptor Positive (ER+) Disease

Genevieve Morris is a highly respected thought leader with more than 10 years of experience in the health IT interoperability trenches.

Metastatic bone disease has proven to be more than agonizing for patients, especially when they discover that their cancer has reached an advanced stage, thereby diminishing their chance of survival and adding to the treatment costs.

Time is of the essence when a newborn baby’s brain is deprived of oxygen. To accelerate critical research in hypoxic-ischemic encephalopathy (HIE), a neonatal brain injury caused by oxygen deprivation and limited blood flow to a baby’s brain, Reiter & Walsh ABC Law Centers has established the Reiter HIE Research Fund.

RDx BioScience, a comprehensive laboratory with opioid expertise supporting valued-based organizations, actively underwrites prescriber education programs and works with self-funded employers, plan sponsors and payers to adopt more cost-effective drug testing programs.